NEOG
Neogen Corporation · Healthcare · Medical - Devices
Momentum inputs (comparable managers):
holder breadth -18.2% ·
share flow -9.5% ·
net new positions -20.0%
· formula
Broad distribution: falling shares and fewer holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q4 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 1 | 0 | 90.75K | $1.06M | n/a | −1 |
| Q2 2026 | 99 | -2 | 145.67M | $1.31B | +8 | −11 |
| Q1 2026 | 105 | +4 | 149.62M | $1.39B | +10 | −7 |
| Q4 2025 | 101 | +1 | 145.41M | $1.02B | +3 | −1 |
| Q3 2025 | 15 | 0 | 86.70M | $495.04M | +1 | −2 |
| Q2 2025 | 13 | +1 | 84.31M | $402.96M | +2 | −1 |
| Q1 2025 | 9 | 0 | 40.38M | $350.08M | +1 | −1 |
| Q4 2024 | 9 | -2 | 40.94M | $497.00M | n/a | −2 |
| Q3 2024 | 10 | 0 | 36.89M | $620.15M | n/a | n/a |
| Q2 2024 | 10 | n/a | 39.27M | $613.84M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Norges Bank ✦ (passive) | 17.48M | -6.9% | $212.17M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 2 | Baillie Gifford ✦ | 9.75M | -13.2% | $118.35M | 0.1% | ▼ Trim | 3 | SEC ↗ ×4 |
| 3 | State Street Global Advisors ✦ (passive) | 8.33M | n/a | $101.10M | 0.0% | n/c | 1 | SEC ↗ |
| 4 | Geode Capital Management ✦ (passive) | 5.12M | -0.6% | $62.15M | 0.0% | ▼ Trim | 3 | SEC ↗ ×2 |
| 5 | T. Rowe Price ✦ | 139.37K | +12.1% | $1.69M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 6 | GAMCO Investors ✦ | 62.13K | +9.9% | $754,258 | 0.0% | ▲ Add | 3 | SEC ↗ |
| 7 | Citadel Advisors ✦ | 24.02K | -97.9% | $291,651 | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 8 | Bridgewater Associates ✦ | 23.37K | -30.3% | $283,724 | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 9 | AQR Capital Management ✦ | 16.53K | -72.3% | $200,699 | 0.0% | ▼ Trim | 3 | SEC ↗ ×2 |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| Millennium Management | $4.80M | was 0.0% |
| Marshall Wace | $1.10M | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 307 holders, 232.63M shares, $1.97B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
Officer, Director · CEO · 505 sh @ 11.95 · $6,035
Open-market sales (S)
No open-market insider sales in our coverage window.
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology